Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
China SXT Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. China SXT Pharmaceuticals shares (SXTC) are listed on the NASDAQ and all prices are listed in US Dollars. China SXT Pharmaceuticals employs 97 staff and has a trailing 12-month revenue of around USD$5.8 million.
|52-week range||USD$0.888 - USD$5.12|
|50-day moving average||USD$2.9401|
|200-day moving average||USD$1.6183|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.075|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing China SXT Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of China SXT Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
China SXT Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, China SXT Pharmaceuticals shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
China SXT Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$424,668.
The EBITDA is a measure of a China SXT Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$5.8 million|
|Operating margin TTM||0.75%|
|Gross profit TTM||USD$2.7 million|
|Return on assets TTM||0.12%|
|Return on equity TTM||-43.83%|
|Market capitalisation||USD$39.8 million|
TTM: trailing 12 months
There are currently 1.2 million China SXT Pharmaceuticals shares held short by investors – that's known as China SXT Pharmaceuticals's "short interest". This figure is 15.1% up from 1.1 million last month.
There are a few different ways that this level of interest in shorting China SXT Pharmaceuticals shares can be evaluated.
China SXT Pharmaceuticals's "short interest ratio" (SIR) is the quantity of China SXT Pharmaceuticals shares currently shorted divided by the average quantity of China SXT Pharmaceuticals shares traded daily (recently around 13.9 million). China SXT Pharmaceuticals's SIR currently stands at 0.09. In other words for every 100,000 China SXT Pharmaceuticals shares traded daily on the market, roughly 90 shares are currently held short.
However China SXT Pharmaceuticals's short interest can also be evaluated against the total number of China SXT Pharmaceuticals shares, or, against the total number of tradable China SXT Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case China SXT Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 China SXT Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.019% of the tradable shares (for every 100,000 tradable China SXT Pharmaceuticals shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against China SXT Pharmaceuticals.
Find out more about how you can short China SXT Pharmaceuticals stock.
We're not expecting China SXT Pharmaceuticals to pay a dividend over the next 12 months.
China SXT Pharmaceuticals's shares were split on a 1:4 basis on 22 February 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your China SXT Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for China SXT Pharmaceuticals shares which in turn could have impacted China SXT Pharmaceuticals's share price.
Over the last 12 months, China SXT Pharmaceuticals's shares have ranged in value from as little as $0.888 up to $5.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while China SXT Pharmaceuticals's is -0.1888. This would suggest that China SXT Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, China SXT Pharmaceuticals has bucked the trend.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of May 2, 2020, it served 116 pharmaceutical companies, 56 pharmacies, and 76 hospitals. The company was founded in 2005 and is based in Taizhou, China.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.